Domvanalimab plus zimberelimab was associated with greater progression-free survival, overall survival, and objective response rate compared with those of zimberelimab or chemotherapy A 36% reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback